Zhejiang Medicine Signs Long-Term Supply Contract With Hospira
This article was originally published in PharmAsia News
Executive SummaryZhejiang Medicine has signed a supply contract with Hospira, an American specialty pharmaceutical and medication delivery company. Under the agreement, Zhejiang Medicine will provide Hospira vancomycin hydrochloride raw materials from April 30, 2008 to Dec. 31, 2017, with an expected total amount of $120 million. Taking into consideration the fluctuating Chinese yuan renminbi and U.S. dollar exchange rate, both sides have decided on the May 1, 2007 rate of $1 to 7.7 yuan as a benchmark. However, if the fluctuation exceeds 10 percent and lasts 90 days, both sides will adjust the value according to the new exchange rate at that point in time. (Click her for more - Chinese language)
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.